You are here
CERID Bibliography
Export 7 results:
Author Title Type [ Year
] Filters: Keyword is Trypanosoma cruzi and Author is Gelb, Michael H [Clear All Filters]
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem. 2010 ;53(10):3887-98.
. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett. 2009 ;19(23):6582-4.
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem. 2009 ;52(12):3703-15.
. Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol Biochem Parasitol. 2008 ;157(1):32-43.
. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A. 2003 ;100(25):15149-53.
